Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) is scheduled to release its earnings data after the market closes on Monday, November 13th. Analysts expect Cyclacel Pharmaceuticals to post earnings of ($0.38) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.10. The firm had revenue of $0.37 million during the quarter. On average, analysts expect Cyclacel Pharmaceuticals to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Cyclacel Pharmaceuticals Trading Down 6.7 %
Shares of CYCC stock opened at $0.54 on Friday. Cyclacel Pharmaceuticals has a 12 month low of $0.28 and a 12 month high of $1.24. The firm has a market capitalization of $6.84 million, a PE ratio of -0.28 and a beta of 1.06. The firm has a fifty day simple moving average of $0.45 and a two-hundred day simple moving average of $0.54.
Wall Street Analyst Weigh In
Hedge Funds Weigh In On Cyclacel Pharmaceuticals
Hedge funds have recently modified their holdings of the company. Schonfeld Strategic Advisors LLC boosted its holdings in shares of Cyclacel Pharmaceuticals by 25.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 770,400 shares of the biotechnology company’s stock worth $514,000 after buying an additional 155,200 shares during the last quarter. Millennium Management LLC increased its holdings in Cyclacel Pharmaceuticals by 6.5% in the 4th quarter. Millennium Management LLC now owns 208,062 shares of the biotechnology company’s stock worth $139,000 after acquiring an additional 12,617 shares during the last quarter. Renaissance Technologies LLC raised its stake in Cyclacel Pharmaceuticals by 166.0% in the 3rd quarter. Renaissance Technologies LLC now owns 167,600 shares of the biotechnology company’s stock valued at $245,000 after acquiring an additional 104,600 shares during the period. Two Sigma Investments LP purchased a new stake in Cyclacel Pharmaceuticals during the third quarter valued at about $98,000. Finally, HRT Financial LP purchased a new position in shares of Cyclacel Pharmaceuticals in the fourth quarter worth about $27,000. Institutional investors own 16.33% of the company’s stock.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.
- Five stocks we like better than Cyclacel Pharmaceuticals
- Canada Bond Market Holiday: How to Invest and Trade
- Data giants MongoDB and Snowflake just got upgraded
- What is the FTSE 100 index?
- Plug Power at tipping point; it’s make or break time for hydrogen
- What Are Defense Contractor Stocks? How to Invest in Defense
- Palantir’s Q3 earnings beat: Time to buy despite analyst caution?
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.